TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases

RT @jwjacobs12: Have to give a shout out to @VUMCPathology Dr. Ridas Juskevicius who made several diagnoses utilizing p53 IHC in challengin…

Have to give a shout out to @VUMCPathology Dr. Ridas Juskevicius who made several diagnoses utilizing p53 IHC in challenging MDS cases. Glad to have learned from the entire hemepath dept @VUMChealth @AdamSeegmiller

RT @sanamloghavi: TP53 mutations are the most common mutation (~40%) in t-MDS, so in this case the IHC stain is super helpful as a surroga…

TP53 mutations are the most common mutation (~40%) in t-MDS, so in this case the IHC stain is super helpful as a surrogate because mutations lead to accumulation of the protein and over-expression by IHC https://t.co/DKKJvybLLE #Hemepath #leusm